In a clinical study, Zaltrap was shown to help extend survival rates in people with metastatic colorectal cancer. In this study, people given Zaltrap in combination with standard chemotherapy lived 13.5 months, on average, compared to 12.1 months for people receiving only standard chemotherapy.
In addition, those receiving Zaltrap plus standard chemotherapy lived 6.9 months before their cancer started progressing (known as progression-free survival). The progression-free survival for people receiving just standard chemotherapy was 4.7 months.
Some general considerations to keep in mind during treatment with Zaltrap include the following:
- This medication is usually given as a slow injection into a vein (an intravenous, or IV, infusion) once every two weeks.
- Zaltrap is normally given by a healthcare provider in a healthcare setting, such as a hospital or clinic.
- The dose is given slowly, over about an hour. If you will be receiving other chemotherapy medicines, you will normally be given Zaltrap first.
- For this drug to work properly, it must be used as prescribed.
The dose of Zaltrap your healthcare provider recommends will vary, depending on:
- Your weight
- How well you tolerate the medication.
As is always the case, do not adjust your dose unless your healthcare provider specifically tells you to do so.
(Click Zaltrap Dosage for more information.)